Canaccord raised the firm’s price target on Verona Pharma (VRNA) to $44 from $37 and keeps a Buy rating on the shares. The firm said they reported Q3 results and noted Ohtuvayre initial sales beat ...
Q3 2024 Earnings Call Transcript November 4, 2024 Verona Pharma plc beats earnings expectations. Reported EPS is $-0.08819, ...
Verona Pharma isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are ...
Verona Pharma has agreed a new $400 million debt facility with Oxford Finance and Hercules Capital designed to help the company navigate the possible approval and launch of ensifentrine ...
Verona Pharma (Nasdaq: VRNA) is already recording millions of dollars in revenue after launching its lead drug in August ...
Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more ...
UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD) drug ensifentrine, setting up regulatory filings in the first half of next year.
Verona Pharma ( (VRNA) ) has released its Q3 earnings. Here is a breakdown of the information Verona Pharma presented to its investors. Verona ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback